Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Arnott

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Nature Reviews. Cardiology|June 16, 2026
Role of systemic and epicardial adipose tissue in cardiometabolic diseaseShaun Khanna, Gurkeerat Mann, Aditya Bhat, et al.
European Heart Journal|December 5, 2019
Sex differences in heart failureCarolyn S P Lam, Clare Arnott, Anna L Beale, et al.
The Lancet. Planetary Health|December 14, 2024
The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trialBenjamin Talbot, Robert A Fletcher, Bruce Neal, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
International Journal of Cardiology|September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trialsJie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Nature Reviews. Cardiology|June 16, 2026
Role of systemic and epicardial adipose tissue in cardiometabolic diseaseShaun Khanna, Gurkeerat Mann, Aditya Bhat, et al.
European Heart Journal|December 5, 2019
Sex differences in heart failureCarolyn S P Lam, Clare Arnott, Anna L Beale, et al.
The Lancet. Planetary Health|December 14, 2024
The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trialBenjamin Talbot, Robert A Fletcher, Bruce Neal, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
International Journal of Cardiology|September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trialsJie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
Pageof 16